Patent: 8,128,929
✉ Email this page to a colleague
Summary for Patent: 8,128,929
| Title: | Antibodies against PDGFRa |
| Abstract: | The invention provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides methods for neutralizing activation of PDGFRα and methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents. |
| Inventor(s): | Nick LOIZOS, Jim Huber |
| Assignee: | University of Washington , Philadelphia Health and Education Corp , ImClone LLC |
| Application Number: | US11/917,890 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,128,929
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | LARTRUVO | olaratumab | Injection | 761038 | October 19, 2016 | 8,128,929 | 2026-06-19 |
| Eli Lilly And Company | LARTRUVO | olaratumab | Injection | 761038 | July 10, 2017 | 8,128,929 | 2026-06-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 8,128,929
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006138729 | ⤷ Start Trial |
| United States of America | 2009110678 | ⤷ Start Trial |
| United States of America | 2012027767 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
